缺陷型HIV-1 DNA pol序列与HIV-1 DNA水平无关并携带多数APOBEC背景耐药突变
本研究纳入613例接受抗逆转录病毒治疗且病毒抑制或血浆病毒载量低于200拷贝/mL的患者,分析HIV-1 DNA基因型耐药检测中缺陷型pol序列的相关因素及其与APOBEC背景耐药突变的关系。结果显示30.3%样本存在缺陷型序列,与HIV-1 DNA水平无关,78%的APOBEC背景耐药突变位于缺陷型序列中,这些突变未在血浆病毒群体中出现,可能不影响抗逆转录病毒治疗病毒学应答。
要点
- 613例HIV-1 DNA基因型耐药检测中186例(30.3%)检出缺陷型pol序列。
- 缺陷型pol序列与HIV-1 DNA水平无关联。
- 226个APOBEC背景耐药突变中78%位于缺陷型序列,未在血浆病毒群体中出现。
核心结论
- 缺陷型pol序列与HIV-1 DNA水平无关,且携带多数APOBEC背景耐药突变,这些突变可能无临床影响,不应在常规实践中报告。
- 需要制定HIV-1 DNA基因型耐药检测报告共识指南,尤其针对APOBEC背景耐药突变的评估与管理。
研究设计与样本
- 纳入接受抗逆转录病毒治疗且病毒抑制或血浆病毒载量低于200拷贝/mL、成功测序蛋白酶、逆转录酶和整合酶区域的患者,进行HIV-1 DNA基因型耐药检测。
- 测序采用Sanger法或Sentosa® NGS方法(20% cut-off),所有超突变序列和/或含至少一个终止密码子的序列视为缺陷型。
- 共分析613例HIV-1 DNA基因型耐药检测。
主要发现
- 186例样本(30.3%)检出缺陷型序列,包括65条蛋白酶序列、92条逆转录酶序列和65条整合酶序列。
- 未发现包括HIV-1 DNA水平在内的因素与缺陷型pol序列检测相关。
- 所有序列中共记录226个APOBEC背景耐药突变,其中78%位于缺陷型序列。
- APOBEC背景耐药突变未在血浆病毒群体中出现,可能不影响抗逆转录病毒治疗的病毒学应答。
临床怎么用
- 作者认为APOBEC背景耐药突变可能无临床影响,不应在常规实践中报告。
- 作者建议需要制定HIV-1 DNA基因型耐药检测报告共识指南,尤其针对APOBEC背景耐药突变的评估与管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The specificity of HIV-1 DNA genotypic resistance tests (GRTs) is hampered by the detection of the APOBEC-context drug resistance mutations (AC DRMs), usually harboured by replication-incompetent proviruses. We sought factors associated with defective sequences in the HIV-1 pol region. In addition, AC DRMs and their link with defective sequences were investigated. METHODS: We included ART-treated patients with viral suppression or plasma viral load (VL) lower than 200 copies/mL, who underwent HIV-1 DNA genotyping, with successful sequencing of protease (PR), reverse transcriptase (RT) and integrase (IN) regions. Sequencing was performed using either the Sanger method or the Sentosa® NGS approach with a 20% cut-off. All hypermutated sequences and/or those containing at least one stop codon were considered defective. RESULTS: A total of 613 HIV-1 DNA GRTs were analysed. Defective sequences were identified for 186 samples (30.3%) including 65 PR sequences, 92 RT sequences and 65 IN sequences. No association, including HIV-1 DNA levels, was found with the detection of defective pol sequences. A total of 226 AC DRMs were recorded in all sequences. Most of these mutations (78%) were harboured by defective sequences. AC DRMs did not emerge in the plasma viral population, and likely do not impact the virological response to ART. CONCLUSIONS: Defectives pol sequences were not associated with HIV-1 DNA levels and harboured most of the AC DRMs. Such mutations likely have no clinical impact, and should not be reported in routine practice. Consensus guidelines for reporting HIV-1 DNA GRTs are needed, especially for the assessment and management of AC DRMs.
引用
- Alidjinou EK, Coulon P, Tetart M, et al. Defective HIV-1 DNA pol sequences are not associated with HIV-1 DNA levels and drive most APOBEC-context drug resistance mutations. J Antimicrob Chemother. 2025. PMID: 39849847. doi:10.1093/jac/dkaf016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。